• Equity PC Ratio   0.57
  • |
  • Index PC Ratio   1.14
  • |
  • Total PC Ratio   0.97
  • |
  • VIX PC Ratio   0.54
  • VIX 12.68
  • VXN 15.86
  • VXO 13.51
  • ISEE 85.00

TruCharts Trading Strategies and Stock Buy/Sell Reports
(Show Details)


Chart Settings
No saved settings found!

Chart Type:
From: / / To: / /
Show detail in :
 Chart Skins:      
Price Overlays:





Indicator Windows:





Company Profile

Teva Pharmaceutical Industries Limited engages in the development, production, and sale of a range of generic and branded pharmaceuticals, biogenerics, and active pharmaceutical ingredients (APIs) worldwide. The company?s principal products include Copaxone for multiple sclerosis; and Azilect for Parkinson?s disease. Teva Pharmaceutical also provides specialty pharmaceutical products, which include respiratory products based on its proprietary delivery systems, including Easi-Breathe, an advanced breath-activated inhaler; Spiromax/Airmax, a multidose dry powder inhaler; Steri-Nebs, the blow-fill-seal based nebulizers; and Cyclohaler, a single dose dry powder device. The company?s branded respiratory products include ProAir, a short-acting beta-agonist for the treatment of bronchial spasms and exercise-induced bronchospasm; and Qvar, an inhaled corticosteroid for long-term control of chronic bronchial asthma. In addition, it offers APIs for respiratory, cardiovascular, anti-cholesterol, central nervous system, dermatological, hormones, anti-inflammatory, oncology, immunosuppressants, and muscle relaxants. Further, the company provides women?s health care products, such as oral contraceptives, intrauterine contraception, and hormone therapy treatments for menopause/perimenopause, as well as therapies for use in infertility and urinary incontinence. It also holds a biotechnology platform focused on the development of peptide and protein-based medicines. Teva Pharmaceutical has cooperation agreements with Kowa Company, Ltd.; Lonza Group Ltd.; H. Lundbeck A/S; Impax Laboratories, Inc.; Anchen Pharmaceuticals, Inc.; sanofi-aventis; and OncoGenex Pharmaceuticals. The company was founded in 1901 and is headquartered in Petach Tikva, Israel.

YES
     
TEVA (Teva Pharmaceutical Industries Limited American Depositary Shares)
Last Trade 9.7701 Date 11/14/2019
Change % 1.67 % Price Change 0.17
Open 9.6 52 Week High 0.0
High 9.97 52 Week Low 0.0
Low 9.53 Type stock
Volume 24282785 Average Volume 0
Prev Close 9.61 Stock Exchange NYSE
Bid 9.77 Ask 9.78
Bid Size 368 Ask Size 153
1st Yr Estimated EPS Growth 2.5017 2nd Yr Estimated EPS Growth 0.0859
2 Years Forward Earning Yield 0.2853 2 Years Forward PE Ratio 3.5047
2 Years EV/Forward EBIT 8.2166 2 Years EV/Forward EBITDA 7.1408
Book Value per Share 12.6272 Book Value Yield 1.314
Buy Back Yield CAPE Ratio
Cash Return -0.0012 Cash Flow per Share 0.5364
Cash Flow Yield 0.0558 Dividend Rate
Dividend Yield 5 Year Dividend Yield
Earning Yield -0.4058 EV/EBIT
EV/EBITDA EV / Free Cash Flow
EV / Forward EBIT 9.2361 EV / Forward EBITDA 7.611
EV / Forward Revenue 2.1052 EV / Pre Tax Income
EV / Revenue 2.0916 EV / Total Asset 0.6377
Expected Dividend Growth Rate Free Cash Flow per Share -0.039
Free Caash Flow Ratio Free Cash Flow Yield -0.0041
Forward Calculation Style Forward Dividend Yield
Forward Earning Yield 0.2627 Forward PE Ratio 3.8066
Forward Return on Asset 0.0482 Forward Return on Equity 0.2
Normalized PE Ratio 13.327342 Payout Ratio 0.0
PB Ratio 0.761057 PB Ratio 10 Year Growth -0.107332
PB Ratio 3 Year Growth 1.042664 Cash Ratio 3 Year Average 1756.9027
Price to Cash Flow Ratio 17.916737 PEG Payback 2.6396
PEG Ratio 1.1194 PE Ratio
PE Ratio 10 Year Average 83.088166 PE Ratio 10 Year Growth
PE Ratio 10 Year High 1665.5 PE Ratio 10 Year Low 10.074286
PE Ratio 1 Year Avg PE Ratio 1 Year High
PE Ratio 1 Year Low PE Ratio 3 Year Avg 668.2039
PE Ratio 5 Year Avg 194.125238 PE Ratio 5 Year High 1665.5
PE Ratio 5 Year Low 15.786517 Free Cash Flow Ratio 10 Year Growth
Free Cash Flow Ratio 3 Year Avg 15.56756 Price Change 1 Month 1.179141
Price to Cash Ratio 8.456873 Price / EBITDA
Price to Sales Ratio 0.592297 Price to Sales Ratio 10 Year Growth -0.162423
Price to Sales Ratio 3 Year Avg 0.964107 Price to Sales Ratio 5 Year Avg 194.125238
Sale per Share 16.225 Sales Yield 1.6883
Sustainable Growth Rate -0.2923 Tangible Book Value per Share -20.827
Tangible Book Value per Share 3 year Avg -31.8319 Tangible Book Value per Share 5 year Avg -20.3298
Total Asset per Share 52.4188 Total Yield
Working Capital per Share -1.433 Working Capital per Share 3 Year Avg -1.1494
Working Capital per Share 5 Year Avg -0.266 Beta 2.502527